How did Skyrizi and Rinvoq perform in AbbVie's first quarter, and how do their results compare to analyst expectations?

Skyrizi recorded $4.48 billion in sales for the first quarter, representing 30.9% year-over-year growth and exceeding Wall Street estimates of $4.41 billion; Rinvoq sales grew 23.3% to $2.12 billion, also surpassing analyst expectations of $2.04 billion.

What was the impact of Humira's patent expiry on AbbVie's first-quarter performance, and how did actual sales compare to forecasts?

Humira's global sales fell 38.6% to $688 million in the quarter due to biosimilar competition following its 2023 U.S. patent exclusivity loss, slightly missing analysts' expectation of $696.5 million.

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026

AbbVie reported better-than-expected quarterly revenue driven by growth in Skyrizi and Rinvoq, offsetting declines in Humira sales. The company raised its full-year earnings forecast while noting strong performance in its neuroscience portfolio.

reuters

2026-04-29

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

2026-06-30

US House committee opens investigation into Merck, AbbVie China drug trials

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

FAQ